List of Artificial Intelligence Companies in China - 22

Overview: AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design. The company’s hybrid based approach, which uses computational drug design followed by wet lab validation, greatly reduces the time and cost necessary for traditional drug discovery efforts. Accutar is committed to building strong partnerships, and collaborates across academia and the pharmaceutical industry to solve interdisciplinary problems. The company was founded in 2015 and has locations in both Shanghai, China and New York, NY. Products & Services: Accutar offers two software packages: Chemi-Net and Orbital. Chemi-Net is a molecular graph convolutional network for accurate drug property prediction. It was recently shown to improve the accuracy of ADME property prediction by a large margin in comparison to the widely-used methods https://arxiv.org/abs/1803.06236. Orbital is a deep neural network based docking platform. The prediction accuracy of protein-ligand complex (holo) from ligand free state (apo) structure is significantly higher than current standards. In addition to these tools, AccutarBio offers services in virtual screening for lead discovery; intelligent-SAR for lead optimization and drug property prediction.

Convalife Pharmaceuticals is an innovative pharmaceutical company that specializes in drug research and development for tumor diseases. They are dedicated to developing innovative drugs and focus on antibody biopharmaceuticals and small molecule treatments.

DIAGENS is a Hangzhou-based biotechnology firm, providing in-vitro diagnostic (IVD) products and other medical equipment.

Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases.

Exegenesis Bio is a clinical stage global gene therapy company with operations in Philadelphia, Boston and China. The company’s innovative gene therapy pipeline is based on proprietary capsids, promoters and unique protein engineering designs. Two programs have advanced to the clinical stage: (1) Type I Spinal Muscular Atrophy (SMA) AAV gene therapy in China (2) neurovascular AMD (wet AMD) rAAV gene therapy in USA The company has built state-of-the-art cGMP manufacturing facilities that include 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids. Exegenesis Bio has raised over $150 M since inception in 2019 and currently employs over 200 scientific and operations staff worldwide. Website: https://www.exegenesisbio.com/ Contacts: Company Information: Contact@ExegenesisBio.com Business Development: BD@ExegenesisBio.com Careers: Careers@ExegenesisBio.com

Great Bay Bio (GBB), based in Hong Kong, is an innovative biotech company with a vision of Disruptive Revolution of Biologics Development. Committed to utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long timelines, high costs, and low success rates in drug development, and in industries involving bioprocessing, e.g., synthetic biology, IVD and CGT. Led by a team of experienced professionals in biopharmaceuticals and AI, GBB's members boast over 20 successful IND filings approved by both China and the United States. GBB has launched multiple proprietary AI biotech platforms; AlfaCell, an AI-enabled site-specific integration cell line development platform that resolves multiple developmental bottlenecks, including unpredictable cell line stability and labor-intensive screening during CLD. Additionally, the AlfaMedX platform is an AI-enabled cell culture media development platform, responsible for creating over 50 unique cell culture media that outperform commercially available CHO cell culture media. GBB has secured 40+ patent applications, related to AI-enabled biological platform. Recognizing the potential of these platforms, GBB has formed partnerships with over 20 leading domestic and international companies.

Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders. In order to meet the highest international standards, Hua Medince developed a powerful internal research quality supervision system Q (QC/QA) based on the advanced open innovation model VIC (VC + IP + CRO).

Leman Biotech Co., Ltd. is a spin-off of EPFL co-founded by Prof. Li Tang (Head of Laboratory of Biomaterials for Immunoengineering). Leman Biotech aims at developing and commercializing new metabolic cancer immunotherapies. Recently, the start-up company closed a US$11 million angel financing round. The money raised will enable it to accelerate the preclinical studies of biomolecule and cell based therapies and prepare for entering clinical trials. The headquarter of the company is now in Shenzhen, a highly vibrant city with the highest number of start-ups per head of population in China. Currently, Leman Biotech is launching a new drug discovery center in Lausanne, Switzerland, to initiate clinical trials in Europe.

Shenzhen Liying Biotechnology Co., Ltd. is a synthetic biology company based on the foundation of structural biology and cutting-edge artificial intelligence computation. We specialize in protein design and modification, providing high-quality and efficient research and development services for various protein applications, as well as the synthesis of protein materials. The company’s core technology founders and team members have over a decade of experience studying in the UK, with deep expertise in protein structure and function cultivated at top international universities and research institutions such as the University of Oxford, the University of Cambridge, and the Francis Crick Institution. They possess comprehensive technical workflows for advanced protein performance optimization and design that is internationally recognized. We have assembled a scientific advisory team at the Nobel Prize and Royal Academy Fellow level, as well as experts of high caliber from both domestic and overseas talent pools. Additionally, they have established extensive connections in industry, policy, and resources through the Chinese Central Organization Department’s Thousand Talents Program.

NeoCura is a high-tech enterprise that relies on AI technology to create an RNA technology platform and conduct R&D of innovative drugs. The company has built multi-omics big data acquisition platforms and multiple bioomics databases. It uses AI and bioinformatics technology to conduct in-depth drug target mining and fully automated drug design for innovative RNA technology platform upgrades and drug research. It has established leading R&D centers and production centers in Beijing, Shenzhen, and Guangzhou to support pipelines development, platform upgrades, and clinical demand.

A global biotech company commited to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need. We design novel CNS-tropic AAV capsids and innovative gene expression cassettes to achieve efficient, effective, and safe gene therapies for severe CNS disorders.

NewDEL Biotech is a biotechnology company based in Shenzhen, China, established in 2021. The company focuses on the research and development of new drugs, with a particular emphasis on innovative drugs designed for tumors. NewDEL Biotech utilizes DNA Encoded Library technology to significantly improve the success rate of drug development.

Nutshell Therapeutics Inc. Inventing small molecule in the realm of drug discovery fostered by protein dynamics. Leveraging our cutting-edge technology based on protein dynamics, Nutshell

About Us As a contract research organization (CRO) in pharmaceutical R&D and clinical studies, Panacro Pharmaceutical Technology Co., Ltd. is committed to providing overall solutions for clinical studies & IND and NDA of chemical & biological drugs and vaccines. Since its establishment in 2004, Panacro has provided professional technical services to hundreds of customers at home and abroad in 20+ major therapeutic fields. In addition, it established offices in 20 major provinces or cities in China. With complete and detailed standard operating procedures (SOPs), and a professional team operating in accordance with international standards (ICH-GCP), it has built close cooperation with 80% study sites in China. Panacro focuses on providing customers with quality and efficient professional services, in order to shorten the product marketing cycle, and facilitate the product marketization. By virtue of a professional technical team and an operation team operating in strict accordance with relevant standards, as well as professional and efficient quality service, we provide customers with highly customized solutions in a rigorous and pragmatic way based on the principle of sincere cooperation and honest operation.

Founded in 2008, Beijing PINS Medical Co., Ltd., is an innovative medical company specializing in R&D, production, and sales of full-range neuromodulation products, including stimulators for deep brain, vagus nerve, spinal cord, and sacral nerve. PINS Medical devotes itself to providing cutting-edge treatments for patients who suffer from neurological disorders such as Parkinson's disease, epilepsy, chronic pain, and uroclepsia. The name of PINS is derived from "Programmable Implanted Neuromodulation Stimulator" and is also an acronym of "patient is no. 1, always." This speaks to the goals of PINS Medical, which are to enhance patient well-being and restore hope, with a focus that goes beyond business to improving society for all citizens. As the incidence of neuropsychiatric disorders continues to rise, placing an increased burden on societies worldwide, PINS Medical, together with research centers, companies, and top academic scientists, will continue to develop the latest cutting-edge therapies and bring them to patients as rapidly and affordably as possible.

Qitan Technology is a developer of genome sequencing technology, specializing in nanopore sequencing. The company has released datasets and publications related to its technology and has made significant technological achievements in the field of genetic code information.

Reetoo is a leading company for AI-driven IVD equipments in the world with revolutionary and innovative IVD equipments for blood, leucorrhea, sperm, urine, and tissues; All of our products are fully automatic in the whole process based on our AI-driven DeepCell engine,which can greatly improve doctors' efficiency and save a lot of time for doctors and patients.We are looking for distributors globally now,please contact us if you are interesting.

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make the R&D easy for innovative biologics”.

TCRCure Biopharma Corp is a world-class, “One-Stop Shop” cell therapy operation built across the U.S. and China. We deliver the latest cell therapy advances directly to patients with solid tumors. As of 2021, we have treated more than 50 patients and built more than a dozen CAR-T/TCR-T pipelines. TCRCure’s cutting-edge platform technologies include antigen-specific TCR/CAR discovery, immune-cell engineering, and industry-scale viral vector production. We operate 40,000 sq. ft. of specialized facilities on both sides of the Pacific, including scalable GMP capacity for cell production and viral manufacturing. TCRCure works closely with world-class hospitals in China and the United States for clinical research in different solid tumors. Current indications including cervical cancer, ovarian cancer, nasopharyngeal carcinoma, lung squamous carcinoma, melanoma, sarcoma, endometrial cancer, and brain cancer.

Westlake Genetech (Hangzhou) Co., Ltd. is an innovative biotech company, a start-up from scientific research achievements of Westlake University. We focus on the rapid development of first-in-class drugs by integrating the 3H (high throughput, high precision, high dimension) biotechnological data production and deep learning modeling. By building technology-driven gene therapy technology platforms and developing differentiated self-developed gene therapy products, we are committed to mapping the full-process implementation of AI-powered gene therapy. Westlake Genetech adheres to the development strategy of "platform + pipeline" dual-wheel drive, actively invests in R&D innovation that combines technological leadership and industrial feasibility, and promotes the technological and commercial landing of AI technology in the vertical field of biomedicine. Our self-developed AI-powered full-chain gene therapy technology platform has evolved to generate a large number of non-liver-targeted AAV capsids, developed gene editing tools with independent intellectual property rights, explored new targets, and developed safe, efficient, and accessible gene therapy innovative therapies for rare diseases, tumors, and other diseases. With the platform's empowerment, it will effectively expand the scope of gene therapy indications, significantly shorten the pipeline development time, improve the pipeline R&D efficiency, and achieve the optimization of cost reduction and efficiency improvement and technology tool selection. We are rapidly advancing our technological achievements to the field of disease treatment, laying out ex vivo and in vivo gene therapy, developing differentiated gene therapy products, and solving more unmet clinical needs.

YolTech Therapeutics is a biotech focuses on combining mRNA and gene editing technology to develop next-generation mRNA drugs and in vivo gene editing drugs.Our company is a pre-clinical stage gene editing biotech, has built leading genome editing platform and mRNA-LNP library. It possesses strong capability of novel Cas and base editors discovery and exceptional production capacity for LNP drug manufactory, with strong IP protection globally. It has created a pipeline with 10 genetic medicines focusing on cardiovascular diseases, infectious diseases and rare diseases.

自由能计算，化学结构预测；小分子对接；小分子对接计算或者模拟 计算化学，Python ，分子对接，机器学习，数据模型，人工智能，分子对接软件，Amber 软件，Autodock，Schrodinger, MOE，Gaussian 软件，tensorflow, Git, GitHub. 数据分析和建模"，"化学信息学"，"生物信息学"，"量子化学"，"计算化学软件开发"